AB0249 Influence of autoantibodies profile on disease activity measurement in a colombian cohort of rheumatoid arthritis patients
BackgroundTraditionally, the role of Rheumatoid Factor (RF) and/or Anti-citrullinated antibodies (ACCP) presence have characterised for diagnosis and prognosis of Rheumatoid Arthritis (RA). However, Anti-nuclear antibodies (ANA) are not routinely measured for the diagnosis of the disease or RA progn...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 1306 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.06.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundTraditionally, the role of Rheumatoid Factor (RF) and/or Anti-citrullinated antibodies (ACCP) presence have characterised for diagnosis and prognosis of Rheumatoid Arthritis (RA). However, Anti-nuclear antibodies (ANA) are not routinely measured for the diagnosis of the disease or RA prognosis establishment during first appointment. Recently, evidence showed that positive ANA titles could be considered as poor prognosis factor for RA, and also a higher probability of developing immunogenicity against biologic therapies.ObjectivesTo compare the disease activity measurement from a Colombian cohort of patients with RA, based on their auto-antibodies profile.MethodsThe study used a cohort of Colombian patients with RA. A database was developed using the information from the clinical records. The data included were: RF, ACCP, ANA, and the disease activity measured using DAS-28 ESR. Disease activity results were obtained in the following periods of time: 0, 3, 12, 24 and 36 months. Patients were classified based on the different autoantibody profiles (RF/ACCP/ANA:—, +–, -+-, –+, ++-, +-+, -++, +++). Mean DAS-28 ESR results from each period of time were calculated. Also mean weekly Methotrexate (MTX) dose was calculated for each profile. Mean differences between initial, and the follow-up period were calculated using Kruskal-Wallis test. Statistical analysis was made using STATA 12.0 software.Results635 patients with RA were included. 32% of them were men, and 68% were women. Mean age was 54.3 years. The most prevalent profile was +++with 118 patients, and the less frequent was +–. Patients with +++profile had the best response to treatment over time, but also they required more MTX dose. Less response during time was observed with +– profile, however the amount of patients from these group was relatively low. As it was expected,—profile patients required less weekly MTX dose (9.26 mg). It was interesting that patients with –+profile present a worst outcome based on DAS-28 activity, and less response to the treatment.ConclusionsResults from the study suggest the importance of including the measurement of ANA titles in the initial categorization and follow-up of patients with RA. The presence of ANA seems to have a worst prognosis. ANA co-existence with ACCP appear to have a worst outcome, compared to ++- or +-+profile. Auto-antibody profile in RA could direct the best therapeutic strategy for each patient. Validation of these results are required based on other cohorts.Reference[1] Sanmarti R, Gomez-Puerta JA. Biomarcadores en la artritis reumatoide. Reumatol Clin. 2011;6(S3):S25–S28.Disclosure of InterestNone declaredAbstract AB0249 – Table 1Auto-antibodies profile, disease activity by DAS-28 ESR (initial and follow-up to 3, 12, 24 and 36 months) and mean weekly MTX dose in a Colombian cohort of RA patientsPROFILE(FR/ACCP/ANA)DAS-28 (INITIALDAS-28 (3 MONTHS)NDAS-28 (12 MONTHS)NDAS-28 (24 MONTHS)NDAS-28 (36 MONTHS)NMEAN WEEKLY MTX DOSE (mg) —3.317.3072603730.1267188640.9367073*410.8593334*309.26+–3.375−0.29057157−0.58066676−0.264857270.17410.82-+-3.434.263663920.6267033*910.7705405*740.6138596*5714.01–+3.201.031481527−0.2926087230.1705263190.80384611310.2++-4.123.8346712**731.048**661.23**510.533816.19-++3.542.3822857560.5656604*530.71325*400.8733333*3314.91+-+4.6951.57*121.77*143.35962.03215.69+++4.118.6474576*1180.9343478**1151.196**861.25**6615.83*p<−0.05 **p<0.001 |
---|---|
AbstractList | Background Traditionally, the role of Rheumatoid Factor (RF) and/or Anti-citrullinated antibodies (ACCP) presence have characterised for diagnosis and prognosis of Rheumatoid Arthritis (RA). However, Anti-nuclear antibodies (ANA) are not routinely measured for the diagnosis of the disease or RA prognosis establishment during first appointment. Recently, evidence showed that positive ANA titles could be considered as poor prognosis factor for RA, and also a higher probability of developing immunogenicity against biologic therapies. Objectives To compare the disease activity measurement from a Colombian cohort of patients with RA, based on their auto-antibodies profile. Methods The study used a cohort of Colombian patients with RA. A database was developed using the information from the clinical records. The data included were: RF, ACCP, ANA, and the disease activity measured using DAS-28 ESR. Disease activity results were obtained in the following periods of time: 0, 3, 12, 24 and 36 months. Patients were classified based on the different autoantibody profiles (RF/ACCP/ANA:-, +-, -+-, -+, ++-, +-+, -++, +++). Mean DAS-28 ESR results from each period of time were calculated. Also mean weekly Methotrexate (MTX) dose was calculated for each profile. Mean differences between initial, and the follow-up period were calculated using Kruskal-Wallis test. Statistical analysis was made using STATA 12.0 software. Results 635 patients with RA were included. 32% of them were men, and 68% were women. Mean age was 54.3 years. The most prevalent profile was +++with 118 patients, and the less frequent was +-. Patients with +++profile had the best response to treatment over time, but also they required more MTX dose. Less response during time was observed with +- profile, however the amount of patients from these group was relatively low. As it was expected,-profile patients required less weekly MTX dose (9.26 mg). It was interesting that patients with -+profile present a worst outcome based on DAS-28 activity, and less response to the treatment. Conclusions Results from the study suggest the importance of including the measurement of ANA titles in the initial categorization and follow-up of patients with RA. The presence of ANA seems to have a worst prognosis. ANA co-existence with ACCP appear to have a worst outcome, compared to ++- or +-+profile. Auto-antibody profile in RA could direct the best therapeutic strategy for each patient. Validation of these results are required based on other cohorts. Reference [1] Sanmarti R, Gomez-Puerta JA. Biomarcadores en la artritis reumatoide. Reumatol Clin. 2011;6(S3):S25-S28. Disclosure of Interest None declared *p<-0.05 **p<0.001 BackgroundTraditionally, the role of Rheumatoid Factor (RF) and/or Anti-citrullinated antibodies (ACCP) presence have characterised for diagnosis and prognosis of Rheumatoid Arthritis (RA). However, Anti-nuclear antibodies (ANA) are not routinely measured for the diagnosis of the disease or RA prognosis establishment during first appointment. Recently, evidence showed that positive ANA titles could be considered as poor prognosis factor for RA, and also a higher probability of developing immunogenicity against biologic therapies.ObjectivesTo compare the disease activity measurement from a Colombian cohort of patients with RA, based on their auto-antibodies profile.MethodsThe study used a cohort of Colombian patients with RA. A database was developed using the information from the clinical records. The data included were: RF, ACCP, ANA, and the disease activity measured using DAS-28 ESR. Disease activity results were obtained in the following periods of time: 0, 3, 12, 24 and 36 months. Patients were classified based on the different autoantibody profiles (RF/ACCP/ANA:—, +–, -+-, –+, ++-, +-+, -++, +++). Mean DAS-28 ESR results from each period of time were calculated. Also mean weekly Methotrexate (MTX) dose was calculated for each profile. Mean differences between initial, and the follow-up period were calculated using Kruskal-Wallis test. Statistical analysis was made using STATA 12.0 software.Results635 patients with RA were included. 32% of them were men, and 68% were women. Mean age was 54.3 years. The most prevalent profile was +++with 118 patients, and the less frequent was +–. Patients with +++profile had the best response to treatment over time, but also they required more MTX dose. Less response during time was observed with +– profile, however the amount of patients from these group was relatively low. As it was expected,—profile patients required less weekly MTX dose (9.26 mg). It was interesting that patients with –+profile present a worst outcome based on DAS-28 activity, and less response to the treatment.ConclusionsResults from the study suggest the importance of including the measurement of ANA titles in the initial categorization and follow-up of patients with RA. The presence of ANA seems to have a worst prognosis. ANA co-existence with ACCP appear to have a worst outcome, compared to ++- or +-+profile. Auto-antibody profile in RA could direct the best therapeutic strategy for each patient. Validation of these results are required based on other cohorts.Reference[1] Sanmarti R, Gomez-Puerta JA. Biomarcadores en la artritis reumatoide. Reumatol Clin. 2011;6(S3):S25–S28.Disclosure of InterestNone declaredAbstract AB0249 – Table 1Auto-antibodies profile, disease activity by DAS-28 ESR (initial and follow-up to 3, 12, 24 and 36 months) and mean weekly MTX dose in a Colombian cohort of RA patientsPROFILE(FR/ACCP/ANA)DAS-28 (INITIALDAS-28 (3 MONTHS)NDAS-28 (12 MONTHS)NDAS-28 (24 MONTHS)NDAS-28 (36 MONTHS)NMEAN WEEKLY MTX DOSE (mg) —3.317.3072603730.1267188640.9367073*410.8593334*309.26+–3.375−0.29057157−0.58066676−0.264857270.17410.82-+-3.434.263663920.6267033*910.7705405*740.6138596*5714.01–+3.201.031481527−0.2926087230.1705263190.80384611310.2++-4.123.8346712**731.048**661.23**510.533816.19-++3.542.3822857560.5656604*530.71325*400.8733333*3314.91+-+4.6951.57*121.77*143.35962.03215.69+++4.118.6474576*1180.9343478**1151.196**861.25**6615.83*p<−0.05 **p<0.001 |
Author | Mendez, P. Quintana, G. Florez, J.B. Coral, P. |
Author_xml | – sequence: 1 givenname: J.B. surname: Florez fullname: Florez, J.B. organization: Rheumatology, Fundacion Santa Fe de Bogota, Bogotá DC, Colombia – sequence: 2 givenname: G. surname: Quintana fullname: Quintana, G. organization: Rheumatology, Fundacion Santa Fe de Bogota, Bogotá DC, Colombia – sequence: 3 givenname: P. surname: Mendez fullname: Mendez, P. organization: Rheumatology, Fundacion Santa Fe de Bogota, Bogotá DC, Colombia – sequence: 4 givenname: P. surname: Coral fullname: Coral, P. organization: Rheumatology, Fundacion Santa Fe de Bogota, Bogotá DC, Colombia |
BookMark | eNpNkEtOwzAQhi1UJNrCHSx1nWInIXaWUPGoVIkNrK1xMlZdJTY4DlJ3SIiLchLclgWref8z883IxHmHhCw4W3JeVNfgXNji2Ld2yHLGZYZjB2EpbmR9Rqa8rGRKV2xCpoyxIivrSlyQ2TDsUsgkl1PydXvH8rL--fxeO9ON6Bqk3lAYowcXrfatxYG-BW9slyqOplUIA1Joov2wcU_7FI4Be3SRWkeBNr7zvbbgkrf1IR70jldC9LalEOI22GiTKkSbpoZLcm6gG_Dqz87J68P9y-op2zw_rle3m0zzXNZZVTagsRUixwKhZpBrrIQWZaG5FAYEKzm2rDatlgaB6dZUjcg5SjRcMCzmZHHSTe-8jzhEtfNjcGmlypngXIiyFKmrOnXpfqfegu0h7BVn6gBc_QOuDsDVEbg6AC9-AbtXgAs |
ContentType | Journal Article |
Copyright | 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
Copyright_xml | – notice: 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
DBID | 3V. 7X7 7XB 88E 88I 8AF 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9- K9. LK8 M0R M0S M1P M2P M7P PQEST PQQKQ PQUKI PRINS Q9U |
DOI | 10.1136/annrheumdis-2018-eular.7589 |
DatabaseName | ProQuest Central (Corporate) Health & Medical Collection (ProQuest Medical & Health Databases) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection BMJ Journals ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection (Proquest) (PQ_SDU_P3) Consumer Health Database ProQuest Health & Medical Complete (Alumni) Biological Sciences Consumer Health Database Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database Biological Science Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic |
DatabaseTitle | ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest Central Student |
Database_xml | – sequence: 1 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2060 |
GroupedDBID | --- .55 .GJ .VT 0R~ 23M 2WC 39C 3O- 3V. 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOFX ACPRK ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FRP FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IGG IHR INH INR IOF J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PQQKQ PROAC PSQYO Q2X R53 RHF RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP 7XB 8FK K9. PQEST PQUKI PRINS Q9U |
ID | FETCH-LOGICAL-b1289-64cabed772e3ea90a2be67b743b187fa7041ed09fdb8fea0bdf6c721e8ef170e3 |
IEDL.DBID | BENPR |
ISSN | 0003-4967 |
IngestDate | Thu Oct 10 18:44:11 EDT 2024 Wed Aug 21 03:27:41 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b1289-64cabed772e3ea90a2be67b743b187fa7041ed09fdb8fea0bdf6c721e8ef170e3 |
OpenAccessLink | https://ard.bmj.com/content/annrheumdis/77/Suppl_2/1306.1.full.pdf |
PQID | 2071177447 |
PQPubID | 2041045 |
ParticipantIDs | proquest_journals_2071177447 bmj_primary_10_1136_annrheumdis_2018_eular_7589 |
PublicationCentury | 2000 |
PublicationDate | 20180600 20180601 |
PublicationDateYYYYMMDD | 2018-06-01 |
PublicationDate_xml | – month: 06 year: 2018 text: 20180600 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Annals of the rheumatic diseases |
PublicationYear | 2018 |
Publisher | BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group LTD |
SSID | ssj0000818 |
Score | 2.3052542 |
Snippet | BackgroundTraditionally, the role of Rheumatoid Factor (RF) and/or Anti-citrullinated antibodies (ACCP) presence have characterised for diagnosis and prognosis... Background Traditionally, the role of Rheumatoid Factor (RF) and/or Anti-citrullinated antibodies (ACCP) presence have characterised for diagnosis and... |
SourceID | proquest bmj |
SourceType | Aggregation Database Publisher |
StartPage | 1306 |
SubjectTerms | Autoantibodies Citrulline Diagnosis Immunogenicity Immunoglobulins Methotrexate Patients Prognosis Rheumatoid arthritis Rheumatoid factor Statistical analysis |
Title | AB0249 Influence of autoantibodies profile on disease activity measurement in a colombian cohort of rheumatoid arthritis patients |
URI | http://dx.doi.org/10.1136/annrheumdis-2018-eular.7589 https://www.proquest.com/docview/2071177447 |
Volume | 77 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEA7uLogX8YlvAnqt9hGT9CS7srIKiogLeytJM8EV2q77-AH-czPZFA-C55ZSvkxmvplJ5iPkSkq0CpFGLnwzl6AwG0mb8SgVQpiMM8hivCj8_MJHY_Y0uZ2EgtsiHKtsfaJ31KYpsUaOlRDsLzIm7mZfEapGYXc1SGh0SC9NGLZpe4Phy-vbry-WiWw181jOxSa5DDomKPMy_4BVZaYLZyqJjADPfV47_uzYZkdXn3-8sw85DztkO3BF2l8v7i7ZgHqPbD6Hbvg--e4PcBQffWyFRmhjqVotG4fWVDd4PpAGTW7a1DT0YiheZUDFCFr91gfptKaK4gTrCoeQU9TNnS_xe_7vXWY-NdRZ2YefgUTDNNbFARk_DN_vR1GQVIi0C0R5xFmpNBhHqSEDlccq1cCFdjRCJ1JYJWKWgIlza7S0oGJtLC9dkggSbCJiyA5Jt25qOCK0ZC7y54nUpaNU3ArFcytSCZCVJmdGHZMbB2IxWw_NKHyykfkL0C3sBcJeeNgLhP2YnLWAF2En4Tvtup_8__iUbPll9BWSM9Jdzldw7gjDUl-QjpiIi2AbP8tRw5Q |
link.rule.ids | 315,786,790,12083,21416,27955,27956,31752,33777,43343,43838,74100,74657 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1NT-MwEB0tRWK5INgPLVDAEnvNbtJ4beeEWtSqXWi1WoHELbLjsVqkJtCPH8A_x2MccVhpz4miaDyeeTNjvwfwXSnyCtlLfPrmvkDhLlEuF0lPSmlzwTFP6aLwdCbG9_z3w6-H2HBbx2OVbUwMgdo2FfXIqRNC80XO5dXTc0KqUTRdjRIaO7BLlJuqA7uD4ezP3_dYrDLVaubxQsg9uIw6JiTzsprjdmkXa-8qmUqQzn3-8PjZo80ds3z8JzqHlDM6hIOIFVn_bXGP4APWn2BvGqfhn-GlPyAqPjZphUZY45jebhpvrYVp6Hwgi5rcrKlZnMUwuspAihFs-d4fZIuaaUYM1ksiIWekm7va0PfC3_vKfGGZ97J54EBikY11_QXuR8O763ESJRUS4xNRkQheaYPWQ2rMURep7hkU0ngYYTIlnZYpz9CmhbNGOdSpsU5UvkhEhS6TKeZfoVM3NX4DVnGf-YtMmcpDKuGkFoWTPYWYV7bgVh_DT2_E8umNNKMMxUYeLkC3Zi_J7GUwe0lmP4Zua_Ay7iR6p133k_8_voCP47vpbXk7md2cwn5Y0tAt6UJns9rimQcPG3MePeQVlRDFow |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ZS8QwEA4esPginngb0Ndqu41J-iRei-ciouBbSZoJrrCt7vED_OfOxBQfBJ9bSvkymXxzZD7GDrUmq1DdBI9vgQGK8In2uUy6SimXSwF5SheFH_ry-kXcvp68xv6ncWyrbH1icNSuqShHTpkQqi8KoY59bIt4vOydfnwmpCBFldYopzHL5pWQJxiIzZ9f9R-ffv2yznSrnycKqTrsIGqakOTL6A2mQzcYo9lkOgHqAT1CLo3Mc9YO3_946nD89JbYYuSN_OxnoZfZDNQrrPMQK-Or7OvsnMby8ZtWdIQ3npvppEHkBrahXkEe9bl5U_NYl-F0rYHUI_jwN1fIBzU3nKZZD2kgOScN3dGEvhf-HqP0geNocW9hHhKPk1nHa-yld_V8cZ1EeYXE4qFUJFJUxoJDeg05mCI1XQtSWaQUNtPKG5WKDFxaeGe1B5Na52WFASNo8JlKIV9nc3VTwwbjlUAWUGTaVkivpFdGFl51NUBeuUI4s8mOEcTy42eARhkCjzxchm5hLwn2MsBeEuybbKcFvIy7it5pbWDr_8f7rIPGUd7f9O-22UJY0ZA42WFzk9EUdpFHTOxeNJBveoXJ1w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AB0249+Influence+of+autoantibodies+profile+on+disease+activity+measurement+in+a+colombian+cohort+of+rheumatoid+arthritis+patients&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Florez%2C+JB&rft.au=Quintana%2C+G&rft.au=Mendez%2C+P&rft.au=Coral%2C+P&rft.date=2018-06-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=77&rft.spage=1306&rft_id=info:doi/10.1136%2Fannrheumdis-2018-eular.7589&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |